The Pfizer pharmaceutical delegate, Albert Bourla, said he “probably” needed a third dose of vaccine refraction against covid-19 within the 12 months he had been completely vaccinated, in order for the vaccination to be complete.
“It’s extremely important to override the group of people who can be susceptible to the virus,” Bourla told the CNBC television channel in a statement stating these juveniles.
The executive also indicates that these doses will be an important remedy for lightening against the variants of the covid that he demonstrated being more contagious.
At the moment, it is being discontinued for some time to protect the vacancies against covid-19, given the shortcomings of this product.
Pfizer recently announced that its vaccination against covid-19 has increased by 91% against viruses and by 95% against severe diseases of the disease and that this protection is maintained during six months after receiving it the first dose.
Asimismo, the people who received the vaccine against the covid-19 of Moderna, whose composition is similar to that of Pfizer, followed by high levels of anticoagulation six months after the second dose, followed by a study published in the scientific journal The New England Journal of Medicine. the principles of my.
The study revealed by Pfizer showed that su vacuna parece funcionar de manera similarly against the variant of the majority virus in South Africa, one of the countries where the product is tested.
Pfizer Pharmaceuticals announced on February 26 that it was studying the possibility of injecting a third dose into people evacuated in order to strengthen the protection against the more aggressive coronavirus variants.
Bourla insures that with this third dose it will be possible to force the response of the anticoagulants between 10 and 20 weeks and suppose that as soon as the person is vaccinated annually against the flu, it tends to take place against covid-19 to be protected.
This new studio is run by two edad groups, las people between 65 and 85 years old and comprises between 18 and 55 and will be elected by the group that participates in the first tests carried out on the Pfizer pharmaceutical in cooperation with BioNTech.
The University of Oxford has initiated a new clinical study to determine whether it is possible to combine doses of the vacancies and obtain an immunological response adequate with the manufacturer’s independent dose.
The investigators are involved in the participation of the AstraZeneca, Pfizer, Moderna and the candidate of the Novavax stadium candidate.